Publicaciones en colaboración con investigadores/as de University of Tübingen (6)

2023

  1. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

    The Lancet, Vol. 401, Núm. 10374, pp. 347-356

2016

  1. The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells

    Oncotarget, Vol. 7, Núm. 16, pp. 21875-21886

2012

  1. The DNA methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells

    International Journal of Cancer, Vol. 130, Núm. 5, pp. 1195-1207

2010

  1. Higher HLA class i expression in renal cell carcinoma than in autologous normal tissue

    Tissue Antigens, Vol. 75, Núm. 2, pp. 110-118

2008

  1. Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines

    Cancer Immunology, Immunotherapy, Vol. 57, Núm. 5, pp. 719-729

2007

  1. International conference: Progress in vaccination against cancer-2006 (PIVAC 6), Granada, Spain

    Cancer Immunology, Immunotherapy